NDAORALFOR SUSPENSION
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEGERID OTC is an over-the-counter combination of omeprazole (a proton pump inhibitor) and sodium bicarbonate in suspension form. It treats frequent heartburn and acid reflux by reducing stomach acid production. The sodium bicarbonate provides rapid buffering while omeprazole offers sustained acid suppression.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30), suggesting stable commercial operations and established market presence rather than rapid growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZEGERID OTC offers limited external career visibility (0 linked job openings) but provides opportunities in mature product commercial management, including brand stewardship, retail sales execution, and competitive positioning. Working on this product involves defending market share in a commoditized OTC category rather than pioneering new therapeutic approaches.
Brand Manager
Worked on ZEGERID OTC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.